Cisneros-Garza LE, Muñoz-Ramírez MR, Muñoz-Espinoza LE, Velarde RVJA, Moreno-Alcántar R, Marín-López E, Méndez-Sánchez N

Language: English
References: 32
Page: 240-247
PDF size: 107.66 Kb.

ABSTRACT

Aim. The aim of this study was to assess the effects of the molecular absorbent recirculating system (MARS) on patients with acute liver failure (ALF) and liver failure with cirrhosis (AoCLF) as well as in cholestatic patients with intractable pruritus in a Mexican population. Material and methods. From August 2003 to December 2011, MARS was used in 38 patients with ALF, 15 patients with AoCLF, and 17 cholestatic patients with intractable pruritus. The patients were examined using a standard liver function test and for vital signs, presence of ascites and encephalopathy before and after each treatment. The therapeutic response, patient status, follow-up status, and need for liver transplantation were determined. Results. Seventy-nine MARS procedures were performed. MARS was used for ALF in 54.3% of patients, AoCLF in 24.2%, and cholestatic disease in 21.5%. There were significant improvements in serum bilirubin (p = 0.000), aspartate aminotransferase (p = 0.000), alanine aminotransferase (p = 0.030), gamma-glytamyl transpeptidase (p = 0.044), alkaline phosphatase (p = 0.006), and encephalopathy grade (p = 0.000). Thirty-eight ALF patients were listed for emergency liver transplantation and treated with MARS; 20 of these patients died on a waiting list, 18 survived. only four underwent liver transplantation and 14 (37%) recovered without transplantation after the MARS procedure. Conclusion. MARS is a safe and effective procedure, especially for ALF patients. Our results suggest that MARS therapy can contribute to native liver recovery in ALF patients.

REFERENCES

1. Sgroi A, Serre-Beinier V, Morel P, Buhler L. What clinical alternatives to whole liver transplantation? Current status of artificial devices and hepatocyte transplantation. Transplantation 2009; 87: 457-66.

2. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, Klammt S, et al. Molecular absorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999; 23: 319-30.

3. Ben Abraham R, Szold O, Merhav H, Biderman P, Kidron A, Nakache R, Oren R, et al. Rapid resolution of brain edema and improved cerebral perfusion pressure following the molecular adsorbent recycling system in acute liver failure patients. Transpl Proc 2001; 33: 2897-9.

4. Ichai P, Samuel D. Extracorporeal liver support with MARS in liver failure: has it a role in the treatment of severe alcoholic hepatitis? J Hepatol 2003; 38: 104-6.

5. Schmidt LE, Wang LP, Hansen BA, Larsen FS. Systemic hemodynamic effects of treatment with the molecular adsorbents recycling system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003: 9: 290-7.

6. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004; 10: 1099-106.

7. Schmidt LE, Sorensen VR, Svendsen LB, Hansen BA, Larsen FS. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transpl 2001; 7: 1034-9.

8. Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, Rodés J. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 1105-10.

9. Acevedo RM, Moreno PJM, Sanz MC, Rubio G EE, Rubio G E, Boullosa GE, Sánchez-Turrión V, Sanz GD, Cuevas-Mons V. Therapy of Intractable pruritus with MARS. Transplant Proc 2005; 37: 1480-1.

10. O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-45.

11. Pauwels A, Mostefa-Kara N, Florent C, Lévy VG. Emergency liver transplantation for acute liver failure. Evaluation of London and Clichy criteria. J Hepatol 17: 124-7.

12. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-9.

13. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978; 23: 398-406.

14. Conn HO. Assessment of mental state. In: Conn HO, Lieberthal MM (eds.) The Hepatic Coma Syndromes and Lactulose. 1st Ed. Baltimore: Williams & Wilkins; 1979, p. 169-88.

15. Heredia D, Caballeria J, Arroyo V, Ravelli G, Rhodes J. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE): a controlled trial. J Hepatol 1987; 4: 293-8.

16. Mc Cormack HM, L’Horne DJ, Sheather S. Clinical applications of visual analog scales: a critical review. Psychol Med 1988; 18: 1007-19.

17. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113: 1264-9.

18. Falkenhagen D, Strobt W, Vogt G, Schrefl A, Linsberg I, Gerner FJ, Schoenhofen M. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 199; 23: 81-6.

19. Rifai K, Ernst T, Kretschmer U, Bahr MJ, Sehneider A, Hafer C, Haller H, et al. Prometheus a new extracorporeal system for the treatment of liver failure. J Hepatol 2003; 39: 984-90.

20. Kribben A, Gerken G, Haag S, Herget-Rosenthal H, Treichel U, Betz C, Sarrazin C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 782-9.

21. Novelli G, Massimo R, Ferretti G, Pugliese F, Roberto F, Lai Q, Novelli S, et al. Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system. Ther Apher Dial 2009; 13: 404-12.

22. Kantola T, Ilmakunnas M, Koivusalo AM, Isoniemi H. Bridging therapies and liver transplantation in acute liver failure. Scan J Surg 2011; 100: 8-13.

23. Camus C, Lavoué S, Gacouin A, Compagnon P, Boudjéma K, Jacquelinet C, Thomas R, et al. Liver transplantation avoided in patients with fulminant hepatic failure who received albumin dialysis with the molecular adsorbent recirculating system while on the waiting list: impact of the duration of therapy. Ther Apher Dia 2009; 13: 549-55.

24. Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Relief Study Group. Extracorporeal Alkbumin Dialysis with Molecular Adsorbent Recirculating System in Acute-on-Chronic Liver Failure: The RELIEF trial. Hepatology 2013; 57: 1153-62.

25. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.

26. Carl DE, Sanyal A. The management of hepatorenal syndrome. Minerva Gastroenterol Dietol 2009; 55: 207-26.

27. Laleman W, Wilmer A, Evenepoel P, Elst I, Zeegers M, Zaman Z, Verslype C, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10: R108.

28. Dethloff T, Tofteng F, Frederiksen HJ, Hojskov M, Hansen BA, Larsen FS. Effect of Prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: a randomized controlled study. World J Gastroenterol 2008; 14: 2065-71.

29. Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, Larsen FS, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-62.

30. Parés A, Deulofeu R, Cisneros L, Escorsell A, Salmerón JM, Caballería J, Mas A. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit Care 2009; 13: R8.

31. Kobashi-Margáin RA, Gavilanes-Espinar JG, Gutiérrez-Grobe Y, Gutiérrez Jiménez AA, Chávez-Tapia NC, Ponciano- Rodríguez G, Uribe M, et al. Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure. Ann Hepatol 2011; 10(Suppl. 2): S70-S76.

32. Méndez-Sánchez N, Chávez-Tapia NC, Espinoza B, Herrera- Gomar M, Zamora-Valdés D, Uribe M. Acute liver failure and the molecular adsorbents recirculating system: Early experience in a tertiary care hospital in Mexico City. Ann Hepatol 2004; 3: 164-6.